Adeka (4401) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
23 Oct, 2026Executive summary
Six-month net sales rose 4.0% year-over-year to ¥195,075 million; operating profit increased 23.6% to ¥18,296 million, and profit attributable to owners of parent rose 8.9% to ¥11,485 million.
Chemicals growth, led by polymer additives, electronic materials and environmental materials, offset declines in Food Products and Life Science.
FY2024 full-year guidance and dividend forecast were raised.
Financial highlights
Ordinary profit rose 8.6% to ¥16,866 million; basic earnings per share increased to ¥112.55 from ¥103.20.
Operating profit rose ¥3.4 billion, supported by higher sales volume, favorable exchange rates and improved net pricing, offsetting a ¥3.3 billion fixed-cost headwind.
Gross profit increased to ¥53,934 million from ¥47,289 million year-over-year.
Operating cash flow rose to ¥33,000 million from ¥26,664 million; cash and deposits were ¥103.9 billion at September 30, 2024.
Comprehensive income fell to ¥8,956 million from ¥20,882 million, reflecting negative foreign currency translation adjustments.
Outlook and guidance
FY2024 guidance: net sales ¥426,000 million, operating profit ¥41,100 million and profit attributable to owners of parent ¥24,500 million.
Operating, ordinary and parent-attributable profit forecasts were raised versus August; net sales and operating profit guidance were also increased.
FY2024 net profit per share is forecast at ¥240.9; the annual dividend forecast was raised to ¥97 per share.
Moderate, stable global growth is expected; Chemicals and Life Science are expected to drive H2 growth, while Food Products faces continued challenges.
FY2026 ADX 2026 targets are net sales of ¥500 billion and operating profit of ¥53 billion.
Latest events from Adeka
- Q1 earnings fell on volume weakness; FY profit targets stayed intact.document-source184401
Q1 2024 - Record FY2023 profits set the stage for ADX 2026 growth and JPY 75 billion in CapEx.4401
Q4 2024 - Pricing and FX cushioned volume-led pressure as FY2023 guidance remained unchanged.4401
Q3 2024 - Strong sales and profit growth led by chemicals and semiconductors; outlook and dividends raised.4401
Q1 2027 - Record FY2025 results; FY2026 forecasts further growth but exclude Middle East impacts.4401
Q4 2026 - Nine-month profit rose 25.1%, led by Chemicals, as semiconductor investment advanced.4401
Q3 2025 - Record FY2024 results, with FY2025 growth forecast amid tariff and cost risks.4401
Q4 2025 - Profit and sales rose, led by Life Science, with stable outlook and higher dividend forecast.4401
Q1 2026 - Profit rose on strong Life Science and Environmental Materials, offsetting Chemicals weakness.4401
Q3 2026